In other embodiments, the delivery system comprises multiple syringes, each syringe of the multiple syringes contains at least one component of the formulation such that each component is pre-mixed prior to injection or is mixed subsequent to injection
CagriSema injection is a long-acting combination therapy under development by Novo Nordisk, the main components are GLP-1 (glucagon-like peptide-1) receptor agonist smeglutide and a long-acting amylin analog cagrilintide
For anecdotal human evidence, high-profile users like Andrew Huberman have reported using BPC-157 for vertebral compression pain with positive results
In some embodiments, the formulations described herein have a practical osmolarity of about 100 mOsm/L to about 1000 mOsm/L, about 200 mOsm/L to about 800 mOsm/L, about 250 mOsm/L to about 500 mOsm/L, about 250 mOsm/L to about 350 mOsm/L, about 280 mOsm/L to about 320 mOsm/L, or about 250 mOsm/L to about 320 mOsm/L
It is also critical for the brain
